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Background: The prognosis of patients with hepatic metastases from neuroendocrine tumors (NET) is 
generally good, and radioembolization with Yttrium-90 microspheres is a locoregional therapy that is used 
in efforts to improve hepatic disease control and survival. This study aims to describe the survival outcomes 
and toxicities associated with radioembolization for hepatic-predominant metastatic NET in a large single-
institution cohort.
Methods: A total of 59 patients underwent radioembolization for metastatic NET with hepatic 
predominant disease at a single academic center.  Patient outcomes were analyzed by Kaplan-Meier survival 
analysis and toxicities were detailed and described. Ten patients within the cohort underwent post-treatment 
dosimetric analysis using PET-MRI and normal liver dosimetry was correlated with hepatic fibrosis and 
toxicity.
Results: Median overall survival from time of radioembolization in the patient cohort was 31 months, 
and the 1- and 2-year overall survival was 80.4% and 65.6% respectively. Median hepatic progression-
free survival and overall progression-free survival were 18 and 13 months, respectively. Three patients died 
of hepatic failure that was possibly therapy-related. Ten patients underwent evaluation of post-treatment 
dosimetry following radioembolization. In patients who did not develop hepatotoxicity or hepatic fibrosis,  
mean dose to normal liver was 25.4 Gy, while the mean liver dose in patients who experienced toxicity (hepatic 
fibrosis in n=2 and death from hepatic failure in n=1) was 59.1 Gy.
Conclusions: Overall survival following radioembolization for hepatic metastases from NET is excellent; 
however, deaths that are potentially treatment-related have been observed. Preliminary data regarding dose 
to normal liver is suggestive of a relation between dosimetry and toxicity, however further work is required to 
further elucidate the mechanism, correlation with dosimetry, as well as additional patient and tumor factors 
that may predispose these patients to toxicity.
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Introduction
Neuroendocrine tumors (NET) are neoplasms originating 
from enterochromaffin cells which typically arise from the 
mid-gut, islet cells in the pancreas, and less frequently, the 
lung or other sites. Although these neoplasms can have an 
indolent course, distant metastases can occur and the liver is 
the most common site (1). Over the past several decades, the 
diagnosis of this tumor has been increasing in incidence (2), 
and many patients have hepatic metastases at the time of 
diagnosis (3). Patients with metastatic NET have good 
long-term prognosis, with median overall survival (OS) of 
24 months for pancreatic NET and 56 months for NET 
arising from the small bowel (2,4). Systemic treatment 
options include cytotoxic chemotherapy, somatostatin 
receptor antagonists such as octreotide, biologic agents 
including everolimus, sunitinib and others, and more recently 
radionuclides such as lutetium dotatate. Loco-regional 
therapies, however, are often attractive options in the setting 
of progressive or symptomatic hepatic metastases. 
Radioembolization using Yttrium-90 (Y90) microspheres 
has been well-described and is now a standard technique to 
provide a targeted loco-regional approach to the treatment 
of liver metastases (5-7). This therapy has been used to 
improve quality of life in patients with refractory symptoms 
related to carcinoid syndrome as well as for definitive 
control of progressive metastases (8). While this treatment 
is generally well-tolerated, there have been reports of 
hepatic toxicity following radioembolization in this patient 
population. This work represents a large single center 
experience in treating patients with metastatic NET using 
Y90, with a focus on survival outcomes and toxicities.
Methods
Patients with liver-predominant metastatic NET treated 
with radioembolization at a single institution from 
2009 through 2015 were included in this analysis.  This 
retrospective study was approved by the institutional 
review board and was compliant with the Health Insurance 
Portability and Accountability Act. Inclusion criteria 
included patients with unresectable liver-predominant 
metastatic NET refractory to systemic therapy, Eastern 
Cooperative Oncology Group (ECOG) performance 
status ≤2, ability to undergo angiography, adequate renal 
function (creatinine ≤2.0 mg/dL), and adequate hepatic 
function (bilirubin ≤2.0 mg/dL). Before radioembolization, 
patient treatment options were discussed at a weekly 
gastrointestinal tumor board meeting attended by 
radiation oncologists, medical oncologists, interventional 
radiologists and hepatobiliary surgeons. Exclusion criteria 
for radioembolization included significant extrahepatic 
disease, gastrointestinal arterial flow that might result in 
extrahepatic deposition, excess lung shunting that would 
result in lung dose >30 Gy, and concurrent chemotherapy 
or radiotherapy. Patients on octreotide continued on the 
medication while receiving radioembolization.
All patients underwent pretreatment evaluation including 
history and physical, laboratory testing, and liver imaging. 
Baseline laboratory tests included complete blood count, 
liver function tests, INR, and chromogranin A. Patients 
were treated with resin (SIR-Spheres, Sirtex Medical, Lane 
Cove, Australia) or glass microspheres loaded with Y90 
(TheraSpheres, MDS Nordion, Kanata, ON, Canada). The 
decision to use resin or glass microspheres was made by the 
treating physician. Pretreatment angiography and 99mTC-
MAA were performed before radioembolization to examine 
the hepatic artery anatomy and assess for gastrointestinal 
arterial flow and lung shunting. Radioembolization was 
performed as previously described (9). All procedures were 
performed on an outpatient basis.
Ten patients included in analysis underwent PET-MRI 
within 24 hours after radioembolization for evaluation of 
post-implant dosimetry as previously described (10). For 
these patients, the whole liver and hepatic tumors were 
individually segmented in MimVista (MIM Software, 
Cleveland, OH) to generate a treated normal liver volume 
(whole liver minus tumor). The Y90 PET images were used 
to generate dose maps and to create dose volume histograms 
(DVH) as previously described by Fowler et al. (10) and 
the minimum delivered dose (Gy) to a given volume of the 
treated normal liver was assessed.
Following radioembolization, patients returned to 
routine clinical follow which typically involved physical 
examination, laboratory testing and imaging at 3 month 
intervals. Dates of expiration were recorded and patients 
were otherwise censored at last clinic follow-up.
Tumor response was assessed using contrast CT or 
MRI images using both mRECIST (11) and EASL (12) 
criteria. Hepatic progression was defined as the appearance 
of new hepatic lesions or enlargement of existing disease. 
Progression-free survival (PFS) was defined as time to any 
progression (hepatic or distant) or death. OS was based 
on all-cause mortality. Clinical and biochemical toxicities 
following radioembolization were assessed using Common 
Terminology Criteria for Adverse Events of the National 
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Cancer Institute (version 4.0).
Al l  ana lyses  were  ca lculated f rom the  date  of 
radioembolization using the Kaplan-Meier method.  For 
PFS and hepatic PFS, patients were censored at date of 
last imaging in the absence of progression. All statistical 
analyses were performed using the R survival package 
available on CRAN at http://cran.r-project.org.
Results
Baseline characteristics
A total of 59 patients were included in analysis. Baseline 
patient characteristics are summarized in Table 1. Median 
patient age was 62 years (range, 26–79 years). Most patients 
were Caucasian and had an ECOG PS of 0. All patients had 
multifocal hepatic disease and bilobar involvement.  The 
majority of patients had primary tumors that originated 
in the pancreas, midgut or an unknown site, and most 
tumors were grade 1 or 2 histologically. Half of patients had 
undergone resection of the primary tumor and most patients 
had liver-only disease. Most patients had prior treatment 
with octreotide. Fourteen patients had undergone prior liver-
directed therapy, including surgery, 13 had received prior 
cytotoxic chemotherapy, and 21 had received prior biologic 
therapy. 
Treatment characteristics
Details regarding the radioembolization treatments 
are described in Table 2. Mean lung shunting at time of 
pretreatment mesenteric angiography was 3%, and only 
4 patients had lung shunting greater than 10%. Thirty-
seven patients required prophylactic embolization of 
selected visceral arteries, such as the gastroduodenal or right 
gastric. Forty-two patients (71%) underwent sequential 
lobar treatments, while 17 patients (29%) received a single 
lobar administration. No patients in the study received a 
single whole liver administration of microspheres. Thirty-
eight patients (64%) underwent radioembolization with 
resin microspheres, while 21 patients (46%) were treated 
with glass microspheres. Mean administered activity was 
1.71 GBq with resin microspheres and 5.43 GBq with glass 
microspheres.
Symptomatic response
Twenty-two patients had symptoms of carcinoid syndrome 
(flushing and/or diarrhea) that was refractory to medical 
therapy prior to radioembolization. Five of these patients 
had documented improvement in symptoms following 
treatment.
Survival
Mean and median follow-up for all patients was 25 and 
26 months, respectively. Mean and median follow-up for 
patients alive at time of analysis was 27 and 29 months. 
Twenty-eight patients had died at time of analysis. Kaplan-
Meier curves for OS, hepatic progression-free survival (PFS) 
and overall PFS are shown in Figure 1. The median OS was 
31 months (95% CI, 27 months to unreached), as shown 
in Table 3. The 1- and 2-year OS was 80.4% and 65.6% 
respectively. Median hepatic PFS was 18 months (95% CI, 
13–27), and 1- and 2-year hepatic PFS were 63.2% and 
37.7%. Median PFS was 13 months (95% CI, 8–19) and 
1- and 2-year PFS were 50.6% and 27.8%. 
Radiographic response
Post-radioembolization imaging was used to assess local 
response to therapy by both mRECIST and EASL criteria 
and is described in Table 4. Seven patients had no imaging 
follow-up and could not be assessed for treatment response. 
Three patients had a radiographic complete response (CR) 
by both mRECIST and EASL criteria. A partial response 
(PR) was noted in 27 patients by mRECIST and 28 patients 
by EASL. Stable disease (SD) was noted in 18 and 15 
patients, respectively and progressive disease (PD) was seen 
in 4 and 6 patients respectively. The overall response rate 
was 58% (30 out of 52 evaluable patients).
Toxicities
Grade 3 or higher clinical or biochemical toxicities were 
noted in a total 9 patients and are detailed in Table 5. Three 
patients developed gastrointestinal ulceration, 4 patients 
had reported encephalopathy, and 2 developed ascites. 
Eighteen patients had grade 3 or higher hematologic 
toxicity, predominantly lymphopenia. In addition, 4 patients 
were noted to have radiographically detected radiation-
induced hepatic fibrosis without clinical sequelae.
There were 3 deaths from hepatic failure that were 
potentially treatment-related. One patient, a 26-year-old 
female with a grade 2 tumor, died 3 months after treatment 
with resin microspheres. She had been treated the prior year 
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Table 1 Baseline patient characteristics






































Clinical variable Value, n (%)






Type of prior therapy
Surgery 7 (11.9)
Chemoembolization 5 (8.5)
Radiofrequency ablation 1 (1.7)



















≤200 cc 25 (46.3)
<200 cc 29 (53.7)
Data missing in pretreatment Chromogranin A (n=36) and tumor 
volume (n=54).
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with chemoembolization and had also previously undergone 
a Whipple procedure. Another patient, a 39-year-old male, 
with grade 1 tumor, died 21 months after sequential bilobar 
infusion with glass microspheres. Imaging features typical 
of cirrhosis were found nine months after Y90 infusion. A 
third subject, a 77-year-old male with grade 3 tumor, who 
had previously undergone a right hepatic trisegmentectomy, 
died 5 months following left lobe treatment from what was 
felt to be radiation-induced liver disease.  
Ten patients in this retrospective cohort were enrolled on 
a prospective institutional study in which they underwent 
post-radioembolization PET-MRI for evaluation of post-
treatment dosimetry. Three of these patients had evidence 
Table 2 Radioembolization treatment characteristics
Technical variable Value





Sequential lobar 42 (71%)
Single (lobar) 17 (29%)
Single (whole liver) 0 (0%)
Glass microspheres 21 (46%)
Activity delivered (GBq) 5.43 (1.83–16.95)
Resin microspheres 38 (64%)
Activity delivered (GBq) 1.71 (0.47–2.25)
Stasis 2 (5%)
Figure 1 Kaplan-Meier survival curves depicting overall survival, 
hepatic progression-free survival and progression-free survival 


















0                10                  20                  30                  40                  50
Table 3 Overall survival (OS), hepatic progression-free survival 
(PFS) and PFS after radioembolization
Clinical response Time from treatment
OS
Median (months) 31 (27–unreached)
1-year (%) 80.4 (70.6–91.5)
2-year (%) 65.6 (53.8–80.1)
Hepatic PFS
Median (months) 18 [13–27]
1-year (%) 63.2 (51.8–77.1)
2-year (%) 37.7 (26.6–53.5)
PFS
Median (months) 13 [8–19]
1-year (%) 50.6 (39.2–65.1)
2-year (%) 27.8 (18.1–42.7)
Table 4 Radiographic response [modified Response Evaluation 
Criteria in Solid Tumors (mRECIST) and European Association 
for the Study of Liver (EASL)] after radioembolization
Radiographic response Number (%)
mRECIST response
Complete response (CR) 3 (5.1)
Partial response (PR) 27 (45.8)
Stable disease (SD) 18 (30.5)
Progressive disease (PD) 4 (6.8)
Unknown 7 (11.9)
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of radiation-induced fibrosis (one with grade 5 hepatic 
failure). Mean delivered radiation dose to the normal liver 
(normal liver defined as volume of treated lobe minus tumor 
volume within treated lobe) was calculated for each of the 
ten patients. Patients who developed hepatic fibrosis had 
higher mean normal liver dose than those without toxicity 
(59.1 vs. 25.4 Gy, P=0.008), shown in Table 5. This is shown 
graphically in the DVH (Figure 2), demonstrating minimum 
delivered dose (Gy) to a given volume of the treated normal 
liver. The DVH curves for the 3 patients with hepatic 
fibrosis demonstrate a larger volume of liver receiving 
20–80 Gy than the patients who did not have toxicity. The 
mean lobar dose and presence or absence of subsequent 
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Absolute lymphocyte 23 14 1
Platelets 11 2 1
Figure 2 Dose volume histograms for the normal hepatic 
parenchyma for the treated lobe for 10 patients who underwent 
assessment of post-radioembolization dosimetry. DVHs for 
patients with hepatic toxicity are shown in red (solid line) and 
for patients without toxicity are shown in blue (dashed line). 
Qualitatively, patients who had greater liver volumes receiving 
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radiotoxicity to the liver in the ten patients who underwent 
assessment of post-radioembolization dosimetry is shown in 
Figure 3.
Discussion
There are many approved systemic and local therapies 
for metastatic NET, however each approach has limits of 
efficacy, toxicity and/or feasibility. Somatostatin analogs 
such as octreotide are useful to treat the symptoms of 
carcinoid syndrome but metastases can eventually become 
resistant to therapy (13). Cytotoxic chemotherapy has 
variable results and can result in significant toxicity (14-16). 
Newer systemic agents include mTOR inhibitors and 
tyrosine kinase inhibitors, as well as peptide receptor 
radionuclide therapy with Lu177-dotatate. Surgical 
management of hepatic metastases can be effective for 
both symptomatic palliation and prolonging OS, but 
is not feasible in the majority of patients due to the 
diffuse multifocal distribution of the metastases (17). 
Transplantation remains as an investigational tool, 
but has had limited success in reported series (18,19). 
Transcatheter arterial approaches (bland embolization 
and chemoembolization) have been well-described and 
are effective at both improving PFS and OS (20). In one 
report, 92% of patients treated with chemoembolization 
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achieved relief of carcinoid symptoms and PFS was 65% at 
1 year (21). However, significant toxicity has been described 
in up to 10% of patients undergoing bland embolization 
for treatment of neuroendocrine metastases (22). 
Radioembolization with Y90 has been well-described in 
the treatment of metastatic NET and was first reported in 
five patients by Simon et al. in 1968 (23). The treatment is 
generally well-tolerated by patients, has a low risk of toxicity, 
and produces tangible radiographic responses (24-27). 
Y90 radioembolization is included in the published 
National Comprehensive Cancer Network guidelines as an 
effective therapy to treat hepatic metastases from NET (28). 
Our current series has demonstrated the benefit of 
radioembolization as seen by a radiographic response 
rate (CR and PR) of 58% in a cohort of patients who had 
generally received one or more types of prior therapy. 
When including those with SD as seen by cross-sectional 
imaging using mRECIST criteria, the overall disease 
control rate was 77%, comparable to the multi-center 
report by Kennedy et al. which reported CR, PR and SD 
rates of 2.7%, 60.5%, and 22.7% respectively (27). Their 
results were based on a three-month follow-up scan using 
a variety of imaging techniques, similar to our patient 
population (27). A single center experience of 40 patients 
demonstrated CR and PR rates of 20.5% and 43.4% and 
OS rates at 1 and 2 years of 72.5% and 62.5% in a cohort 
of patients with similar demographics as in the current 
report (29). This consistent data between studies confirms 
radioembolization as a useful technique to treat patients 
who have progressed on other available medical treatments 
such as systemic chemotherapy, including cytotoxic agents, 
somatostatin analogs, or biological agents.
Several  recent publications have evaluated the 
incidence of hepatic toxicity in patient with metastatic 
NET, particularly since this is a patient population with a 
generally good life expectancy. In one analysis, a cirrhosis-
appearing morphology was seen on cross-sectional 
imaging in 26.7% of patients receiving unilobar infusion 
of microspheres. This rate doubled in those treated with 
whole-liver infusion. Those investigators also noted signs 
of portal hypertension, which was more frequent in patients 
undergoing whole-liver infusion (30). The incidence of 
cirrhosis or fibrosis following Y90 for NET has also been 
reported by others (31-33). Decrease in liver volume, 
another potential metric of fibrosis, was noted in 12% of 
patients treated with sequential bilobar Y90 infusions in 
another study (34). Radiation-induced hepatic fibrosis was 
noted in only 4 out of 52 patients (7.7%) with available 
follow-up scans in the current study. However, whole-liver 
infusion was not used in the current study and the mean 
follow-up was only 2 years. Hepatic fibrosis and remodeling 
after radiation therapy is a slow process, and the clinical 
changes related to the development of portal hypertension 
may not always be apparent until a longer observation 
period is present. 
Though the timeframe for radioembolization-induced 
hepatic fibrosis is over the course of many years, three 
patients in this cohort died of hepatic failure following 
radioembolization (two within 6 months of treatment). 
Two of these patients had previously undergone procedures 
or treatments that may have predisposed them to hepatic 
injury. There have been few reports of fatal toxicities in 
patients with metastatic NET following radioembolization. 
Whitney et al. report an episode of hepatic failure 
one month following radioembolization (35). In their 
retrospective review of toxicities in patients treated at a 
single institution, Su et al. report death from hepatic failure 
in 2 of patients in the absence of disease progression or 






2 65.1 Yes—Gr. 5 hepatic failure
3 37.7 No
4 9.7 No
5 51.7 Yes—radiographic fibrosis
6 30.3 No











^Mean lobar dose to the infused liver lobe minus tumor (as a 
representation of normal liver parenchyma within the treated lobe.
Figure 3 Hepatic toxicity as related to delivered dose administered.
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of liver failure in the setting of disease progression and 
subsequent exposure to potentially hepatotoxic systemic 
therapies (30).  
Significant efforts have been made to correlate prescribed 
activity with actual delivered dose, treatment outcomes 
and toxicities following radioembolization. Ten patients 
in our cohort had undergone post-radioembolization Y90 
PET-MRI to evaluate dose distribution of the delivered 
microspheres. This technique of using PET to quantify 
delivered dose after radioembolization is emerging as a 
strategy to predict response in hepatic tumors (10,36). 
Srinivas et al have used this technique with PET-CT to 
calculate delivered dose to normal liver tissue and has 
shown that a mean dose of 67 Gy to normal liver tissue is 
associated with increased rates of hepatic complications (36). 
Similarly, a relationship between dose and toxicity has been 
described after dosimetric calculations using SPECT-CT (37). 
In our cohort of ten patients, the mean liver dose for 
patients who had hepatic toxicity (defined as hepatic 
fibrosis or hepatic failure) was 59.1 Gy, while the mean 
liver dose for patients without hepatic toxicity was 
25.4 Gy. Due to the multifactorial nature of hepatic failure 
for patients with metastatic cancer (disease progression, 
prior and subsequent local and systemic therapies) and the 
low patient number of patients who underwent analysis of 
post-radioembolization dosimetry, it is impossible to draw a 
firm conclusion regarding the correlation of radiation dose 
to normal liver and incidence of toxicity. However, these 
data are suggestive that delivered dose to normal hepatic 
parenchyma may impact long-term hepatic function.
One of the drawbacks of our study is that it  is 
retrospective and observational. There is no comparison 
group who did not undergo radioembolization and there 
are a relatively small number of total patients, limiting 
statistical analysis.  In addition, it can be difficult ascertain 
the role of radioembolization with regards to subsequent 
morbidities because of confounding variables including 
the use of systemic chemotherapy or biologic agents and 
progression of tumor causing clinical decline independent of 
prior Y90 infusion. The analysis of dosimetry by PET-MRI 
in efforts to correlate dosimetry with toxicity and outcomes 
is still investigational, and very few patients in this study 
underwent this analysis. Furthermore, some of our patients 
had a portion of their treatment done at outside medical 
facilities, rather than our tertiary care center, making data 
capture incomplete.
In conclusion, Y90 radioembolization for hepatic 
predominant metastatic NET results in excellent 
radiographic response rate and good OS. A small proportion 
of patients may develop hepatic toxicity ranging from 
asymptomatic fibrosis to death from liver failure.  More 
work is needed to determine which patients are most likely 
to benefit from radioembolization and which patient, tumor 
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